Pharmaceuticals News and Research

RSS

Derma Sciences adds XTRASORB Foam dressing to advanced wound care product portfolio

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announced the launch of its new XTRASORB™ Foam dressing. The dressing is the company's first novel entry in the $300 million foam wound dressing market. First sales are expected during the second quarter of 2010.

4 May 2010

Reprints Desk launches ePrints NRx scientific article collection service

Derycz Scientific, Inc., the content repurposing company, today announced that its subsidiary Reprints Desk, an award-winning provider of information services and content workflow solutions, has launched ePrints NRx, a new scientific article collection service that simplifies the re-use of PDFs by medical marketers, brand managers and sales professionals.

4 May 2010

MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2010.

4 May 2010

Techne Corporation's consolidated net earnings up 17.2% for quarter ended March 31, 2010

Techne Corporation's consolidated net earnings for the quarter ended March 31, 2010 increased 17.2% to $32.4 million or $.87 per diluted share compared with $27.6 million or $.74 per diluted share for the quarter ended March 31, 2009. The increase in net earnings for the quarter was primarily due to a $4.7 million tax benefit, equating to $.12 per share, resulting from a foreign exchange tax loss on Techne's repatriation of 50 million pound sterling from R&D Systems Europe to its U.S. based parent.

From BiosPacific, Inc. 4 May 2010

Fresenius Medical Care's first-quarter net revenue up 13% to $2,882 million

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced its results for the first quarter of 2010.

4 May 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

4 May 2010

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Impax Laboratories, Inc. today reported significant growth in the first quarter of 2010 due to an increase in sales from its Global product sales channel. Total revenue increased $264.4 million to $323.3 million driven by the successful March 2 exclusive launch of generic Flomax® ($176.2 million of revenue and $167.9 million of gross profit) and continued strong sales of generic Adderall XR® for which there were no comparable amounts in the first quarter 2009, as well as increased sales of the Company's fenofibrate products.

4 May 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical Companies, Inc. today reported results for the first quarter ended March 31, 2010.

4 May 2010

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

4 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

Pro-Pharmaceuticals closes $310,000 private placement tranche

Pro-Pharmaceuticals, Inc., today announced that it has closed a $310,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.4 million.

4 May 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases such as Alzheimer's disease (AD), announced today the detection of the AD-associated aggregated Beta-amyloid (ABeta), the hallmark of AD, in the blood from the most-frequently-used animal model of AD. The assay detects both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD.

4 May 2010

Mylan Pharmaceuticals receives FDA approval for Bupropion HCl ER Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Bupropion Hydrochloride Extended-release Tablets USP, 150 mg, the generic version of GlaxoSmithKline's smoking cessation aid, Zyban.

4 May 2010

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.

4 May 2010

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

MicroStockProfit.com releases investment report on Vical

MicroStockProfit.com announces an investment report featuring Vical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Vanda reports total revenue of $12.4 million for first-quarter 2010

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the first quarter ended March 31, 2010.

4 May 2010

FDA grants market clearance for Illumina's BeadXpress system for multiplex genetic analysis

Illumina, Inc. today announced that the U.S. Food and Drug Administration has granted 510(k) market clearance for the company's BeadXpress system for multiplex genetic analysis.

From Illumina, Inc. 4 May 2010

Pharmaceuticals News and Research

Derma Sciences adds XTRASORB Foam dressing to advanced wound care product portfolio

Reprints Desk launches ePrints NRx scientific article collection service

MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010

Techne Corporation's consolidated net earnings up 17.2% for quarter ended March 31, 2010

Fresenius Medical Care's first-quarter net revenue up 13% to $2,882 million

Celldex reports net loss of $6.6 million for first-quarter 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Pro-Pharmaceuticals closes $310,000 private placement tranche

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Mylan Pharmaceuticals receives FDA approval for Bupropion HCl ER Tablets

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

MicroStockProfit.com releases investment report on Vical

Vanda reports total revenue of $12.4 million for first-quarter 2010

FDA grants market clearance for Illumina's BeadXpress system for multiplex genetic analysis

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News